Skip to main content
graph.swiss
Roche Holding AG

Roche Holding AG

334.20 CHF+2.60 (+0.78%)
XSWX:ROPMarket Closed
ListedCHF265.9BHealthcareDrug Manufacturers - General103,249 employees

Company Profile

Legal NameRoche Holding AG
CEOMr. Zigurds R. Vitols
HeadquartersGrenzacherstrasse 124
Phone41 61 688 88 80
Employees (FTE)103,249
SectorHealthcare
IndustryDrug Manufacturers - General

Other Listings & Derivatives(1)

Business Description

Roche Holding AG is a Swiss biopharmaceutical and diagnostics company headquartered in Basel, Switzerland. The company develops, manufactures, and markets innovative medicines and diagnostic solutions worldwide, with a strong focus on oncology therapies derived from its integration with Genentech. Its bestselling pharmaceutical products target cancer treatment, while the diagnostics division provides centralized and point-of-care testing, bolstered by technologies in cell analysis, gene expression, genome sequencing, and nucleic acid purification. Oncology accounts for a significant portion of pharmaceutical sales, complemented by products serving researchers and healthcare providers. Roche Holding AG operates across healthcare sectors, including drug manufacturing and medical diagnostics, offering tools that support clinical decisions and research advancements. Founded in 1896, it maintains a prominent role in the global biopharmaceutical market through its diverse portfolio of blockbuster therapies and diagnostic innovations.

Profitability & Growth

Profitability

Profit Margin+20.33%
Operating Margin+29.99%
Return on Equity (TTM)+37.27%
Return on Assets (TTM)+12.94%

Recent Year-End

Revenue63.36B
Revenue / Share79.59
Gross Profit47.19B
EBITDA22.21B
Diluted EPS16.05
Earnings Growth YoY+170.90%
Revenue Growth YoY-0.40%

Balance Sheet Snapshot

Total Cash (MRQ)

15.49B

Total Debt (MRQ)

33.20B

Current Ratio (MRQ)

1.38

Book Value / Share

42.48

Stock Statistics

Shares Outstanding795.6M
Float Shares652.9M
Avg Volume (10d)762.8K
Avg Volume (90d)1.1M
% Held by Institutions+43.94%

Valuation

Market Cap265.90B
Enterprise Value285.62B
Trailing P/E20.82
Forward P/E15.40
PEG Ratio15.40
Price / Sales (TTM)4.20
Price / Book (MRQ)7.87
EV / Revenue4.51
EV / EBITDA11.88

Price Summary

52-Week Low243.90
52-Week High374.90
50-Day MA327.46
200-Day MA322.18
Beta0.34

Dividends

Forward Div Rate39.20
Forward Div Yield+11.76%
Trailing Div Rate9.80
5Y Avg Div Yield+330.00%
Payout Ratio+60.47%
Ex-Dividend Date2026-03-12